By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Ligon Discovery today said that it will use its Small Molecule Microarray (SMM) screening platform to discover candidates for Bayer Schering Pharma's drug development programs.

The Cambridge, Mass.-based firm said that its technology works by affixing drug candidates to a slide, enabling it to use cell lysates, instead of "developing a complex assay based on a full understanding of a protein target's functions."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.